Display options
Cite
Barré M, Amatore F, Avenin M, et al. Occurrence of Sézary syndrome following the initiation of anti-IL-5 drug. Eur J Cancer. 2021;156:S41-S42doi: 10.1016/S0959-8049(21)00703-6.
Barré, M., Amatore, F., Avenin, M., Gorvel, L., Olive, D., & Delaporte, E. (2021). Occurrence of Sézary syndrome following the initiation of anti-IL-5 drug. European journal of cancer (Oxford, England : 1990), 156S41-S42. https://doi.org/10.1016/S0959-8049(21)00703-6
Barré, Mathilde, et al. "Occurrence of Sézary syndrome following the initiation of anti-IL-5 drug." European journal of cancer (Oxford, England : 1990) vol. 156 (2021): S41-S42. doi: https://doi.org/10.1016/S0959-8049(21)00703-6
Barré M, Amatore F, Avenin M, Gorvel L, Olive D, Delaporte E. Occurrence of Sézary syndrome following the initiation of anti-IL-5 drug. Eur J Cancer. 2021 Oct;156:S41-S42. doi: 10.1016/S0959-8049(21)00703-6. PMID: 34649655.
Copy Download .nbib Format: NLM
Share it on

Eur J Cancer. 2021 Oct;156:S41-S42. doi: 10.1016/S0959-8049(21)00703-6.

Occurrence of Sézary syndrome following the initiation of anti-IL-5 drug.

European journal of cancer (Oxford, England : 1990)

Mathilde Barré, Florent Amatore, Morgan Avenin, Laurent Gorvel, Daniel Olive, Emmanuel Delaporte

Affiliations

  1. Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France; Service de dermatologie, Hôpital Nord, APHM, Aix Marseille Université, Marseille, France.
  2. Service d'anatomie et cytologie pathologiques, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France.
  3. Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France.
  4. Service de dermatologie, Hôpital Nord, APHM, Aix Marseille Université, Marseille, France.

PMID: 34649655 DOI: 10.1016/S0959-8049(21)00703-6

[No abstract available.]

Keywords: Sézary syndrome; anti-IL-5 monoclonal antibody; benralizumab

Publication Types